Trials / Completed
CompletedNCT00051987
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
A Randomized, Multicenter, Open-Label, Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 175 (planned)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how tumors in patients with colorectal carcinoma respond to treatment with VELCADE alone versus VELCADE given with irinotecan, and also to see what effects (good and bad) it has on you and your cancer.
Detailed description
In this study, patients with colorectal cancer that is no longer responding to standard medical treatment with irinotecan or an irinotecan containing treatment will be randomized to treatment with VELCADE alone or to treatment with VELCADE in combination with irinotecan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VELCADE TM (bortezomib) for Injection, or PS-341 |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2004-03-01
- First posted
- 2003-01-22
- Last updated
- 2008-02-11
Locations
22 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00051987. Inclusion in this directory is not an endorsement.